This is a genuinely clinical evidence base but it is phase-2/phase-3 investigational data, not a finished, approved product
4, the vast majority of the GLP-1 stimulatory activity was present in the greater than 100 kDa fraction of the bacterial supernatants (2507 1000 pM of GLP-1 for JA1, 1998 570 pM of GLP-1 for ATCC 12228 compared to 482 20 pM for the media control) with little activity remaining in the less than 100 kDa fractions (752 625 pM of GLP-1 for JA1, 545.3 363.5 pM of GLP-1 for ATCC 12228, compared to 487 182 pM for the media control) and no activity in the less than 3 kDa fraction (410 131 pM of GLP-1 for JA1, 347 85 pM of GLP-1 for ATCC 12228 compared to 482 20 pM for the media control)
Initially, PDL3 and PDL9 cells were seeded at the same density
BPC-157 Body Protection Compound-157 is a synthetic peptide made up of 15 amino acids
Sural nerve pathology in diabetic patients with minimal but progressive neuropathy
This minimizes the risk of introducing contaminants from the very start